CSPC Pharmaceutical (HKG:1093) granted an exclusive license to Cipla USA to sell its irinotecan liposome injection in the US, according to a Thursday filing with the Hong Kong bourse.
The injection is indicated for the treatment of multiple solid tumors such as metastatic pancreatic cancer, colorectal cancer, lung cancer, and cervical cancer, the filing said.
Under the agreement, CSPC Pharma will get an upfront payment of $15 million and may be eligible to obtain up to $25 million in potential first commercial sale and regulatory milestone payments.
CSPC could also receive up to $1.03 billion in additional commercial sales milestone payments, the filing said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。